Semaglutide results at 6 weeks: what actually happens in the first month and a half

The myth: if nothing dramatic has happened by six weeks, the medicine isn't working

This is the question our prescribers hear most weeks, and it rests on a misunderstanding of how the dose schedule is designed. At six weeks you have almost certainly not yet reached a therapeutic maintenance dose. Wegovy's titration starts at 0.25 mg for the first four weeks, primarily to help your system adjust and reduce early nausea. Week five moves to 0.5 mg. The 2.4 mg dose where the biggest clinical-trial results were recorded is still months away for most people. Expecting dramatic weight loss at six weeks is like expecting a full harvest six weeks after planting.

What you may notice at this stage is subtler: a quieter sense of hunger, smaller portions feeling sufficient, less interest in snacking late in the evening. These shifts in appetite and eating behaviour are the early signal that the medicine is doing its job at the receptor level. They precede visible weight change. If you have lost a small amount of weight, or none yet, that is consistent with being on a starter dose. It is not evidence of failure.

For a broader look at how the timeline of response develops, the full Wegovy timeline guide breaks down what happens month by month in plain terms.

What the trial data actually shows, and where six weeks sits in it

The landmark STEP 1 trial, published in the New England Journal of Medicine, ran for 68 weeks. Participants who reached and stayed on the 2.4 mg maintenance dose achieved an average body-weight reduction of around 15%. That figure is the result of the full treatment arc, titration included. The trial did not report six-week snapshots as primary outcomes because six weeks is within the dose-escalation phase for most participants, it was never positioned as a meaningful checkpoint for weight loss.

Real-world data from clinical services reflects the same pattern: the rate of weight loss tends to accelerate once a person reaches and tolerates higher doses, typically from months three or four onward. Individual variation is wide. Someone with a lot of initial water retention, or who started treatment around a period of high stress or illness, may see very little on the scales at six weeks despite the medicine working exactly as it should.

The twelve-week results page covers the phase where more consistent weight loss typically becomes visible, and the eight-week checkpoint explains what changes between weeks six and eight as the dose continues to increase. For context on the very earliest phase, you can read about what semaglutide results look like at four weeks alongside the week-one experience to build a fuller picture of how the medicine behaves during titration.

Side effects at six weeks: what's normal and what to watch for

Gastrointestinal symptoms (nausea, loose stools, constipation, bloating, reflux) are most common in the early weeks of treatment and after each dose increase. At six weeks you may be moving from 0.25 mg to 0.5 mg, which can bring a fresh wave of mild digestive discomfort. This is expected and does not mean you need to stop. Most people find these symptoms settle within a few days to two weeks at each new dose level.

Staying well hydrated, eating smaller meals, and avoiding high-fat or very spicy food during adjustment periods all help. Fatigue and headache are also reported in early weeks and tend to ease.

One symptom that always warrants prompt attention is severe, persistent stomach pain that radiates toward the back, with or without vomiting. This can be a sign of acute pancreatitis, which the MHRA flagged in a Drug Safety Update in January 2026 as an infrequent but serious known risk with GLP-1 medicines. If that symptom occurs, seek medical help the same day rather than waiting for your next clinical review. Any suspected side effects can be reported directly to the MHRA through the Yellow Card scheme.

Other side effects to take seriously and not manage alone: signs of a severe allergic reaction, sudden changes in vision, or a persistent low mood. Your prescriber and the patient information leaflet are the right place to go with any concern that falls between routine discomfort and genuine alarm.

What six weeks can tell you (and what it cannot

Six weeks can tell you that your body is adjusting to the medicine, that the appetite signals are beginning to shift, and that you are building the habits) smaller portions, more movement, consistent routine, that the treatment is designed to support. You can find a full overview of the treatment on the Wegovy treatment page, including how it works mechanically and what the licensed eligibility criteria look like.

Six weeks cannot tell you your final outcome, whether the medicine will work long-term, or whether your dose is optimal. The NHS's own semaglutide medicine guide notes that treatment should be reviewed at the six-month mark: if less than 5% weight loss has occurred at the highest tolerated dose by then, continuing is reconsidered. That review point is months away; six weeks is still the beginning.

If you are considering starting semaglutide and want to understand whether you are likely to be eligible, you can check your eligibility with a free consultation, reviewed the same day by a GPhC-registered prescriber.